Happy to participate to the 15th Forum for Cellular and Humoral Immunotherapy today at 4pm CET. I will discuss the risks of secondary malignancy after #CARTcell therapy. Feel free to register👉 us06web.zoom.us/webinar/regi...

Honored to present our latest #RomeeLab research on engineering IL-12-secreting CAR NK cells to target high-risk AML—demonstrating feasibility, safety, and efficacy. What a pleasure to be at #EBMT25 in Florence! 🇮🇹🌞

Delighted to see a packed and engaged audience at the Quality Management Session 3 on the 9th edition of the FACT-JACIE standards! #EBMT25

AACR urges Congress to reaffirm its long history of steadfast and bipartisan support for medical research by ensuring that NIH has all of the resources needed to advance its lifesaving mission to prevent, diagnose, and treat cancer and other diseases: AACR.org/NIH

Excited to share this first-in-human evaluation of memory-like NK cells combined with an IL-15 super-agonist, with or without ipilimumab, in advanced head and neck cancer! Kudos to Roman Shapiro and Michal Sheffer for leading this work in the #RomeeLab. jhoonline.biomedcentral.com/articles/10....

This will kill science in the US. This is how China wins. Why is this not on the news? Why are people not more upset about this? grants.nih.gov/grants/guide...

Trump & Musk are making massive cuts to the National Institutes of Health. I know there is a lot going on right now, but this is one of worst things they have done so far, will affect cancer research and trials, the search for cures, innovation and competitiveness, our universities. Your lives.

Academic medicine colleagues, I worry we missed the boat on scientific communication. If we did a better job of explaining what we do and how we do it, half the country wouldn’t be so happy about defunding us right now.

Thank you Rémy for promoting this paper ! This confirmatory study reinforce the body of evidence to vaccine patients against COVID-19 BEFORE and AFTER anti-CD20 immunochemotherapy against Lymphoma

Important report in @nejm.org from @mskcancercenter.bsky.social CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 #CARTcells #mmsm www.nejm.org/doi/full/10....

Happy to share this study! We prospectively evaluated CD4, CD8 T-cell and serological responses to the #COVID19 mRNA vaccine in a B-cell lymphoma patients treated with anti-CD20 therapy. Kudos to Caroline Besson & @sylvainlamure.bsky.social for leading this work. www.frontiersin.org/journals/imm...

Here is another remarkable study by the LYSA, published in @Hemasphere-journal.bsky.social! It evaluates the efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma with matched cohort analysis. Kudos to Amira Marouf for leading this collaborative work. onlinelibrary.wiley.com/doi/full/10....

Happy to share our study on postoperative stage 0 Hodgkin lymphoma published in @hemasphere-journal.bsky.social Congrats to Audrey Couturier and Guillaume Manson for leading this work. Is surgery alone a curative option? Find some answers in our article! ⬇️ onlinelibrary.wiley.com/doi/10.1002/...

After CAR T therapy in France, only one patient developed a T cell malignancy, highlighting a low incidence risk. by Dulery R, Guiraud V (...) Houot R et 10 al. in Nat Med #MedSky 📖 read the article:

🎉Finally published🎉 Clearance of driver mutations after transplantation for myelofibrosis @nejm.org www.nejm.org/doi/full/10....

Happy to share our work published in Nature Medicine! We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...

Disappointing new study showing - once again - that women are leaving research careers at far higher levels than men If you're interested to read about strategies to reverse these types of curves, check out our recent #Cell perspective- link below ⤵️ #WomeninSTEM 👩‍🔬👩🏾‍🔬🧪 www.nature.com/articles/d41...

Analysis of 3,066 patients who received #CARTCell therapy in France, since 2018. Only one patient (0.03%) developed a T-cell malignancy after CAR T infusion, with insertion of the CAR into a tumor suppressor gene. Conclusion: there might be a very low risk of T-cell malignancy after CAR T therapy.

T cell malignancies after CAR T cell therapy in the DESCAR-T registry @naturemedicine.bsky.social @remydulery.bsky.social www.nature.com/articles/s41...

A French study of 3,066 patients who received CAR T-cell therapy found an extremely low incidence (0.03%) of T-cell malignancies post-treatment. Only one case was observed over six years, suggesting the treatment is largely safe in this regard. www.nature.com/articles/s41...

Amazing and very important work for the field. 👏🏽👏🏽👏🏽

Happy to share our work published in Nature Medicine! We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...

Here is a video where I discuss the management and treatment options for patients with DLBCL who are not eligible for CAR T-cell therapy. #VuMedi #CAR_T #lymsm #Medsky www.vumedi.com/video/treati...

From #ASH24 to inpatient leukemia service! Instead of posting articles I will be posting an abstract a day Day 1 - our IIT looking at InO plus TKI in newly diagnosed Ph+ ALL ashpublications.org/blood/articl...

Post-CAR MCL DESCAR-T registry: - 1-yr OS after brexu-cel failure 30% - post-CAR outcomes better with RT (ORR 50%) and BsAb (ORR 43%) - 1-yr OS 57% w/ BsAb - most deaths due to MCL, some infections 2nd #ASH24 dataset showing better outcomes w/ BsAb in MCL post-CAR setting. #lymsm

CAR-T outcomes based on nodal +/- extranodal @gloria_iacoboni #ASH24 - post-CAR OS worse if nodal+EN - ORR worse with increasing # of EN sites - sites w/ worse outcomes: bone, liver, GI, renal/adrenal, pancreas - network analysis reveals connected sites #lymsm #tcellrx

#ASH24 plenary: ketogenic diet & CAR-T efficacy - ketogenic diet➡️cytokine release & CAR expansion in mouse xenograft via beta-hydroxybutyrate - in pts, BHB correlates w/ CAR expansion and giving BHB to 3 pts enhanced T-cell oxphos Fascinating! BHB + CAR-T trial is open. #tcellrx

Brexu-cel ZUMA-2 in BTKi naive pts #ASH24 - 86 pts, mFU 16 mos - 1-yr PFS 75%, OS 90%; 1-yr DOR 80% for responders - 6% G3+ CRS, 21% G3+ ICANS! - COD: 7 deaths d/t AEs My preference is for liso-cel given better toxicity profile (or cytoreduce with BTKi). #lymsm #tcellrx

Excellent data with PEMBRO-GVD in relapsed #Hodgkin lymphoma in study by @mskcancercenter.bsky.social Alison Moskowitz - she will present additional data tomorrow #ash24 #lymsm

A highly anticipated new CAR-T cell therapy for B-cell ALL and a great news for the patients! Congratulations to Claire Roddie and the team behind the FELIX trial, leading to the FDA approval of Obecabtagene autoleucel. Read the full article here: www.nejm.org/doi/full/10....

If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW

🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼 PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼 A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼 doi.org/10.1182/bloo... #MedSky #HemeSky